XORTX Therapeutics Inc
XTSX:XRTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Japan Logistics Fund Inc
TSE:8967
|
JP |
|
Jahez International Company for Information Systems Technology SCJSC
SAU:9526
|
SA |
|
Storskogen Group AB (publ)
STO:STOR B
|
SE |
XORTX Therapeutics Inc
Other
XORTX Therapeutics Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
XORTX Therapeutics Inc
XTSX:XRTX
|
Other
-$738.4k
|
CAGR 3-Years
12%
|
CAGR 5-Years
-86%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Other
-$105m
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
13%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Other
CA$106k
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Other
-$10.2m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-74%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Other
-$522k
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Other
-CA$6.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-49%
|
|
XORTX Therapeutics Inc
Glance View
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-09-30. The firm is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. The company is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
See Also
What is XORTX Therapeutics Inc's Other?
Other
-738.4k
USD
Based on the financial report for Dec 31, 2025, XORTX Therapeutics Inc's Other amounts to -738.4k USD.
What is XORTX Therapeutics Inc's Other growth rate?
Other CAGR 5Y
-86%
Over the last year, the Other growth was -11%. The average annual Other growth rates for XORTX Therapeutics Inc have been 12% over the past three years , -86% over the past five years .
